SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chonkus Maximus is a community driven & operated fan token, dedicated to Chonkus Maximus the Famous chonky cat from Chania, Crete, Greece. A viral TikTok star, known for lounging by the waterfront. A local landmark with a 5.0 Google Maps rating, drawing tourists for photos and social media fame. He went from neighborhood lounge-lizard to global sensation through social media — TikTok, Instagram and Twitter videos tagged with #chonkusmaximus, receiving hundreds of thousands of views. Someone marked his spot on Google Maps as a “destination” — initially as a joke — but it gained traction and reached a consistent 5‑star rating from visitors who came specifically to meet him. His online appeal has even rivaled famous Cretan landmarks like Samaria Gorge and Balos Lagoon, which typically have slightly lower ratings

Chonkus Maximus

Chonkus Maximus is trending as community members observe its constructive market behavior. Discussions highlight the crypto's stable chart, successful retests of support, and potential for expansion. The increased volume and market sentiment suggest growing confidence in $CHONKUS.

Bondex is a web 3.0 professional network where users own part of the ecosystem earn rewards and monetise their network.

Bondex

Bondex ($BDXN) is trending with significant community buzz around a recent token unlock event, which many anticipated would cause a price drop but instead saw the price hold steady. Community members are pointing to strong buying activity and accumulation, with some drawing comparisons to early stages of other successful cryptos. Discussions also highlight Bondex's focus on Web3 career opportunities and recent moves like the Remote3 acquisition.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is trending as community members discuss its real-world utility through the Flexa network and potential for growth, while others express frustration over its stagnant price and question management's actions. Bullish investors highlight its growing partnerships and potential for a significant revaluation once the market recognizes its value, contrasting it with hyped projects lacking tangible applications. Concerns remain about low volume and the need for increased awareness and adoption.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TGL is trending due to unusual price action and volatility following a reverse split, drawing comparisons to SMX and sparking significant community discussion around potential short squeezes. The stock's low float and high short interest are key talking points, with many anticipating a substantial move in the coming days. Community members are actively debating potential price targets and strategies, contributing to the stock's heightened visibility.

The Sandbox is a community-driven platform where creators can monetize voxel ASSETS and gaming experiences on the blockchain.  SAND is the utility token used throughout The Sandbox ecosystem as the basis of transactions and interactions. It is an ERC-20 utility token built on the Ethereum blockchain. There is a finite supply of 3,000,000,000 SAND.

The Sandbox

SAND is trending as community members highlight its potential for a significant run, drawing comparisons to past rallies and noting the accumulation of volume and eyes on the crypto. Bullish sentiment is fueled by factors such as multi-year lows, upcoming potential news catalysts, ties to established brands, and the growing interest in metaverse-related projects. Discussions also mention SAND's market cap and potential for growth within the web3 sector.

Camtek Ltd. engages in the business of developing and manufacturing high-end inspection and metrology equipment for the semiconductor industry. The firm is also involved in inspecting integrated circuits and measuring its features on wafers throughout the production process of semiconductor devices, covering the front and mid-end and up to the beginning of assembly. The company was founded on October 21, 1987 and is headquartered in Migdal HaEmek, Israel.

Camtek Ltd

Camtek ($CAMT) is trending due to positive Q3 earnings results, exceeding revenue and EPS expectations, and Q4 guidance that suggests continued growth. Bullish analysts are raising price targets, citing the company's strong position in high-performance computing and advanced packaging, particularly related to AI and chiplet applications. Community members are highlighting the company's consistent profitability and potential for further upside, with some suggesting it could be a beneficiary of increased demand for AI chips and capital expenditures within the semiconductor industry.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is gaining attention as community members discuss its ecosystem development, including upgrades to the Pi App Studio and a partnership with CiDi Games. Some users are focused on price predictions while others express concerns about unverified balances and exchange listings. Community members are also closely monitoring various smaller tokens, noting shifts in market structure.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. ($INOD) is trending due to speculation surrounding a potential partnership with a major defense contractor like Lockheed Martin or Palantir, fueled by comments from Innodata's CEO about a strategically significant relationship. The community speculates this partnership could be a "game changer," conveying market leadership in AI training for military applications and opening doors to sovereign AI projects in nations like Saudi Arabia and the UAE. Discussions also highlight Innodata's existing AI capabilities and the potential financial impact of a substantial partnership.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

Halozyme (HALO) is trending as community members discuss the potential implications of its patent litigation with Merck, particularly following a recent ruling in Germany, and how this could affect future licensing agreements. Bullish investors believe the market is undervaluing HALO, pointing to strong fundamentals and potential catalysts such as new partnership deals and patent extensions, while some traders are eyeing oversold conditions for a possible bullish reversal. The company's ENHANZE technology and royalty revenue potential continue to be key discussion points.

Codatta

XNY (Codatta) is gaining attention as community members discuss its potential for gains and strong performance against the market, particularly in light of Bitcoin's movements. The coin's chart patterns and recent activity, including a bounce off a support zone, are being watched closely for signs of a breakout and further upward momentum. Some users are also discussing Codatta's fundamentals related to AI/data utility and on-chain fingerprint verification technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Equity

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 


Polyrizon Ltd (PLRZ)&nbsp;led the pack with a 23% increase in weekly followers after the development-stage biotech company dropped plans to undergo a 1-for-10 reverse stock split, which led to shares surging nearly fourfold on Friday.The Israel-based company specializes in preventing biological threats, including allergens and viruses, from penetrating mucosal tissues — an area that has gained new relevance in the post-COVID-19 world.Last month, Polyrizon reported promising preliminary safety results for its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plrz-stock-surges-on-manufacturing-deal-for-trial/cJaVyHWR1U">PL-14</a> Allergy Blocker, a mucoadhesive nasal gel spray designed to create a physical barrier against airborne allergens. The company expects to launch clinical trials in the U.S. and Europe by late 2025 or early 2026.Polyrizon stock has lost over half its value this year.Pheton Holdings (PTHL)&nbsp;saw a 19% rise in retail follower growth over the past week despite the absence of any news catalyst.The Beijing, China-based healthcare solution provider specializes in treatment planning systems for brachytherapy and other related products and services.The company's shares debuted on the Nasdaq in September 2024 and have gained a little over 4% since. However, their performance has been less than stellar year to date, with a loss of over 5%.AirSculpt Technologies (AIRS)&nbsp;posted an 8% jump in weekly Stocktwits follower additions. The body contouring specialist reported better-than-expected quarterly results and forecast full-year revenue of about $160 million to $170 million, which topped Wall Street estimates.Shares of the Miami Beach, Florida-based company, which offers minimally invasive fat removal procedures, have lost over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

A trio of small-cap healthcare stocks caught the attention of retail investors last week, posting sharp jumps in follower growth on Stocktwits. 

Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.&nbsp;Trading volume surged 890 times the daily average, reflecting heightened investor interest in the Israel-based biotech company.The massive rally follows Polyrizon’s announcement of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a prominent European Good Manufacturing Practice (GMP) manufacturer.&nbsp;This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.The PL-14 allergy blocker is part of Polyrizon’s effort to develop innovative nasal sprays that create a hydrogel-based shield in the nasal cavity, protecting against allergens and viruses.&nbsp;The manufacturing deal secures a compliant supply chain for the clinical trial, marking a key milestone for the development-stage biotech firm.Retail chatter on Stocktwits has been overwhelmingly bullish.<stembedurl>https://stocktwits.com/TraderUKBoyy/message/597012617</stembedurl><stembedurl>https://stocktwits.com/Dollarpee/message/597017164</stembedurl>Polyrizon’s stock had a rocky start on the Nasdaq, debuting at the end of October with a disappointing IPO.&nbsp;The company priced 958,903 units at $4.38 per unit, with each unit including one ordinary share and three warrants exercisable at the same price. Shares dropped more than 64% post IPO.Despite the poor debut, Polyrizon has gained 90% so far this year following Wednesday’s surge, although it remains below its IPO price.&nbsp;Over the past month, the stock has seen a meteoric rise in popularity, adding 1,576% more followers on Stocktwits amid a 10,300% spike in message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares